The Bio Report

Orbis Medicines is developing orally available synthetic macrocycles called ⁿCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.

Pharma Boardroom

As pharmaceutical companies race to replace injectable therapies with more accessible oral biologics, Orbis Medicines is leading the charge with its next-generation macrocycle platform and AI-powered discovery engine.

Base to Base Biotech by Jim Cornall

Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.

Endpoints News

European biotech Orbis Medicines has raised €90 million in Series A funding to advance its AI-driven platform for designing oral macrocycle drugs targeting diseases traditionally treated with injectable biologics.

Biopharma Dive

Orbis Medicines has raised $93 million to develop oral macrocyclic peptides that combine the power of biologics with the convenience of pills, aiming to replace injectable drugs for hard-to-treat disease targets.